Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Sang Min Lim

Broad Spectrum Alkynyl Inhibitors of T315I BCR-Abl

Bioorganic and Medicinal Chemistry Letters

Clinical Biochemistry

Pharmaceutical Science

Drug Discovery

2010

English

Related publications

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL T315I Point Mutation

Journal of Hematology and Oncology

English

Small Interfering RNA Against BCR-ABL Transcripts Sensitize Mutated T315I Cells to Nilotinib

Haematologica

Hematology

2010

English

A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl

Journal of Medicinal Chemistry

Drug Discovery

Molecular Medicine

2010

English

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Clinical Lymphoma, Myeloma and Leukemia

English

Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I

English

Oligomerization Inhibition, Combined With Allosteric Inhibition, Abrogates the Transformation Potential of T315i-Positive BCR/ABL

English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica

Hematology

2015

English

BCR-ABL Tyrosine Kinase

Science-Business eXchange

2012

English

The Gatekeeper Mutation T315I Confers Resistance Against Small Molecules by Increasing or Restoring the ABL-kinase Activity Accompanied by Aberrant Transphosphorylation of Endogenous BCR, Even in Loss-Of-Function Mutants of BCR/ABL

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Sang Min Lim

Broad Spectrum Alkynyl Inhibitors of T315I BCR-Abl

Related publications

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL T315I Point Mutation

Small Interfering RNA Against BCR-ABL Transcripts Sensitize Mutated T315I Cells to Nilotinib

A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl

Adherence to BCR-ABL Inhibitors: Issues for CML Therapy

Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I

Oligomerization Inhibition, Combined With Allosteric Inhibition, Abrogates the Transformation Potential of T315i-Positive BCR/ABL

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

BCR-ABL Tyrosine Kinase

The Gatekeeper Mutation T315I Confers Resistance Against Small Molecules by Increasing or Restoring the ABL-kinase Activity Accompanied by Aberrant Transphosphorylation of Endogenous BCR, Even in Loss-Of-Function Mutants of BCR/ABL